Gueudry J, Richez F, Tougeron-Brousseau B, Genevois O, Muraine M
Service d'ophtalmologie, hôpital Charles-Nicolle, 1, rue de Germont, 76031 Rouen cedex, France.
J Fr Ophtalmol. 2010 Nov;33(9):630-6. doi: 10.1016/j.jfo.2010.07.007. Epub 2010 Oct 29.
To assess efficacy and safety of subconjunctival bevacizumab in corneal neovascularization treatment.
The study was a prospective case series that included patients treated with subconjunctival bevacizumab injections for corneal neovascularization over a period of four months. A dose of 2.5 mg (0.1 mL) of bevacizumab (25 mg/mL) was injected into the subconjunctival area 1-2mm behind the limbus near the corneal neovascularization. The main outcome measures were visual acuity, corneal neovascularization, as well as local and general side effects.
Thirteen eyes of 12 patients were included. The mean patient age was 44.2 years (range, 18-87 years). Patients received from two to four bevacizumab injections. The mean corneal neovascularization area decreased from 41.1 to 33.7 % at day 45 (p=0.0003) and to 33.9 % at day 120 (p=0.0013). Median visual acuity changed from 1.32 to 1.28 LogMAR on day 45 and to 1.25 LogMAR on day 120. Subconjunctival bevacizumab was well tolerated without general side effects. There was no significant change in intraocular pressure. An epithelial defect was described in three patients after initiation of bevacizumab therapy.
Subconjunctival bevacizumab injections were effective and safe in reducing corneal neovascularization within the first four months. Meanwhile, improving vision may provide additional strategies.
评估结膜下注射贝伐单抗治疗角膜新生血管的有效性和安全性。
本研究为前瞻性病例系列研究，纳入了在四个月内接受结膜下注射贝伐单抗治疗角膜新生血管的患者。将2.5mg（0.1mL）贝伐单抗（25mg/mL）注射到角膜新生血管附近角膜缘后1-2mm的结膜下区域。主要观察指标为视力、角膜新生血管情况以及局部和全身副作用。
纳入12例患者的13只眼。患者平均年龄为44.2岁（范围18-87岁）。患者接受了2至4次贝伐单抗注射。在第45天时，角膜新生血管平均面积从41.1%降至33.7%（p=0.0003），在第120天时降至33.9%（p=0.0013）。第45天时，视力中位数从1.32 LogMAR变为1.28 LogMAR，第120天时变为1.25 LogMAR。结膜下注射贝伐单抗耐受性良好，无全身副作用。眼压无显著变化。3例患者在开始贝伐单抗治疗后出现上皮缺损。
结膜下注射贝伐单抗在最初四个月内有效且安全地减少了角膜新生血管。同时，改善视力可能提供额外的策略。
